Navigation Links
Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
Date:4/10/2008

SOUTH SAN FRANCISCO, Calif., April 10 /PRNewswire/ -- Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU) is pleased to announce the positive results of a successfully completed Phase 2 trial for CRO-ID (crofelemer for the treatment of acute adult infectious diarrhea) conducted by its partner, Glenmark Pharmaceuticals Limited (BSE: Glenmark). The primary endpoints of the trial were stool weight, duration of diarrhea, stool frequency and stool consistency; additional endpoints followed include degree of patient dehydration and reduction in gastrointestinal index score.

The conclusions from the study were that treatment with crofelemer was well tolerated and resulted in statistically significant improvements in all the primary endpoints and statistically significant reduction in the additional endpoints as well. Overall clinical success was achieved in 79.1% of the evaluable patients receiving crofelemer compared to 28.2% of the evaluable patients receiving placebo.

There were no drug related adverse events associated with crofelemer.

The Phase 2 study was a randomized, parallel group, double-blind, placebo-controlled which enrolled 98 Indian adult male and female patients aged between 18 to 65 years with acute diarrhea defined as the occurrence of three or more unformed stools (soft or watery consistency) within the 24 hour period preceding entry into the study. Patients suffering from acute infectious diarrhea were dosed 250mg of crofelemer, QID (4 times per day) until recovery or for a maximum of three days. Details regarding the stool weight, stool frequency, stool consistency, duration of diarrhea, and other gastrointestinal symptoms were recorded by the investigators at baseline, and days 1, 2 and 3 of treatment. All patients had a scheduled follow-up visit 30 days after the end of the last dose.

In conclusion, adult Indian patients with infectious diarrhea treated with crofelemer showed a faster recovery with the first dose itsel
'/>"/>

SOURCE Napo Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
2. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
3. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
5. Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
6. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
7. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
8. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
9. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
10. Medarex Announces Ipilimumab Program Continues to Move Forward
11. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015 Harwood Feffer LLP ... board of directors of Aerie Pharmaceuticals, Inc. ("Aerie" or ... board has breached its fiduciary duties to shareholders. ... press release announcing results from its first Phase 3 ... release disclosed that in the trial, Rhopressa failed to ...
(Date:4/27/2015)... , April 27, 2015 ... the addition of the "Endoscopy Global Market ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... approximately $43 billion by 2019 growing at around ... drivers for the market growth are aging population, ...
(Date:4/27/2015)... AUSTIN, Texas , April 27, 2015 ... solutions company focused on gynecologic disease, announced ... financial results after the market close on ... investor conference call and webcast at 4:30pm ... 2015 at 4:30pm Eastern/1:30pm Pacific Domestic: , ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3
(Date:4/27/2015)... April 27, 2015 Array Health ... technology, has announced that Lance Hood, senior director of ... fourth annual Direct-to-Consumer Health Care Marketing Summit ... David Smith, Partner and Director of Payer Services, Leavitt ... care consumerism – through a retail/e-commerce perspective – and ...
(Date:4/27/2015)... April 27, 2015 Ticket Down is a ... Philadelphia for his upcoming concert on Sunday, June 21st. ... thrill his countless North American fans again in 2015 when ... his "Out There" tour. He will be performing in ... to listen to this legendary performer for the first time ...
(Date:4/27/2015)... Thanks to a $7.5 million grant ... half-dozen institutions, including American University, will operate in a ... and behavioral research aimed at ending the AIDS epidemic. ... with HIV or AIDS, according to the latest statistics. ... population over the age of 13 was living with ...
(Date:4/27/2015)... Angeles, CA (PRWEB) April 27, 2015 The ... has been to connect clients of personal injury attorneys with ... network of doctors has seen steady growth throughout their history ... Charles E. Richardson, DC and his team in the ... including a medical doctor and massage therapist, patients can find ...
(Date:4/27/2015)... April 27, 2015 Sitting or standing for ... and feel tired, and for those whose occupation requires them ... and taxi cab drivers, or to be on their feet ... the discomfort can be more severe and longer lasting. These ... syndrome. Dr. Madaiah Revana of Northeast Houston Vein Center is ...
Breaking Medicine News(10 mins):Health News:Array Health’s Senior Director of Marketing to Present at The Fourth Annual Direct-to-Consumer Health Care Marketing Summit 2Health News:Paul McCartney Presale Tickets at Wells Fargo Center in Philadelphia: Ticket Down Slashes Paul McCartney Ticket Prices in Philadelphia at the Wells Fargo Center 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 3
... Feb. 26 AIDS Action congratulates Jeffrey Crowley, an ... health care and HIV/AIDS for his appointment as Director ... He joins a well-respected and dedicated team in the ... and reports to Director Melody Barnes who has a ...
... inhibit both normal and virulent strains, study finds ... Combination treatment with two FDA-approved drugs shows promise ... study shows. , In laboratory tests, researchers at ... National Institute of Allergy and Infectious Diseases found ...
... The number of Americans traveling abroad for healthcare is ... trend as the recession worsens and more Americans are left ... to the Deloitte Centre for Health Solutions, the number of ... million in 2010 and 15.75 million by 2017. The $16 ...
... Ignagni, President and CEO of America,s Health Insurance Plans, ... President,s budget:"Today,s budget submission sends a signal to the ... health care. We applaud the President for laying ... to put our nation on a path towards comprehensive ...
... Consultancy, is pleased to announce the launch of a further nine ... listings to relevant specialist industries. , ... (PRWEB) February ... & Marketing Consultancy , is pleased to announce the launch of ...
... RALEIGH, N.C., Feb. 26 Arbor Pharmaceuticals, a ... that the company has launched XYLAREX - a ... otitis media (middle ear,infections). XYLAREX is a ... reduce the number of ear infections children experience. ...
Cached Medicine News:Health News:AIDS Action Applauds President on Appointment of Jeffrey Crowley as Director of National AIDS Policy 2Health News:Antibiotic Combo Fights Resistant TB 2Health News:Americans Will Soon Have Medical Butlers to Assist in Medical Tourism Research 2Health News:AHIP Statement on the President's Budget 2Health News:Simply Marcomms Launch New Specialist Online Industry Directories 2Health News:Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children 2
Mayfield Disposable Adult (plastic) Skull Pins are designed for rigid skeletal fixation....
Endoscopes...
Short system ventriculoscope for free hand use....
Preclude Dura Substitute is the only non-biological membrane designed to "seal" around suture holes. 0.3 mm as nominal thickness....
Medicine Products: